Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 177-183

  Khamaisie, Hazem ^a   Sussan, Sherbel ^a   Tal, Michael ^a,e   Najajreh, Yousef ^b   Ruthardt, Martin ^c   Mahajna, Jamal ^a,d  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b AL QUDS UNIVERSITY   (Palestine)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d TEL HAI COLLEGE   (Israel)

^e Protea Vaccine Technologies Ltd   (Israel)

Author keywords

Antitumor activity; Autophosphorylation; Bcr Abl; CML; Daedalea gibbosa; Kinase; Medicinal mushrooms; Oleic acid

Indexed keywords

ACETIC ACID ETHYL ESTER; ACETONITRILE; BCR ABL PROTEIN; DAEDALEA GIBBOSA EXTRACT; HEXANE; IMATINIB; METHANOL; OLEIC ACID; PLANT EXTRACT; TETRAHYDROFURAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DAEDALEA GIBBOSA; DRUG EFFICACY; DRUG ISOLATION; DRUG PURIFICATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; MOUSE; MUSHROOM; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; SOLVENT EXTRACTION;

AGARICALES; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FUSION PROTEINS, BCR-ABL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, NUDE; OLEIC ACID; PHOSPHORYLATION; PLANT EXTRACTS; PRECURSOR CELLS, B-LYMPHOID; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 79851483983     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mizuno M, Minato K, Ito H, Kawade M, Terai H and Tsuchida H: Anti-tumor polysaccharide from the mycelium of liquid-cultured Agaricus blazei Mill. Biochem Mol Biol Int 47: 707-714, 1999.
2. Zaidman BZ, Yassin M, Mahajna J and Wasser SP: Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67: 453-468, 2005. (Pubitemid 40909591)
3. Petrova RD, Mahajna J, Reznick AZ, Wasser SP, Denchev CM and Nevo E: Fungal substances as modulators of NF-kappaB activation pathway. Mol Biol Rep 34: 145-154, 2007. (Pubitemid 47124940)
4. Yassin M, Wasser SP and Mahajna J: Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int J Oncol 32: 1197-1204, 2008.
5. Faderl S, Talpaz M, Estrov Z and Kantarjian HM: Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131: 207-219, 1999. (Pubitemid 29365004)
6. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R and Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172, 1999. (Pubitemid 29325745)
7. Li S, Ilaria RL Jr., Million RP, Daley GQ and Van Etten RA: The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189: 1399-1412, 1999. (Pubitemid 29227526)
8. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539, 2002. (Pubitemid 34534519)
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937, 2002.
10. Ottmann OG and Hoelzer D: The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia-positive acute lymphoblastic leukemia - promises, pitfalls and possibilities. Hematol J 3: 2-6, 2002. (Pubitemid 34223907)
11. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R and Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias. Lancet Oncol 4: 75-85, 2003. (Pubitemid 36196725)
12. O'Hare T, Corbin AS and Druker BJ: Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16: 92-99, 2006. (Pubitemid 43089618)
13. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C et al: Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 122: 2744-2752, 2008. (Pubitemid 351631376)
14. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al: Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat Chem Biol 2: 95-102, 2006.
15. Cheetham GM, Charlton PA, Golec JM and Pollard JR: Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 251: 323-329, 2007. (Pubitemid 46669805)
16. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E et al: Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355-4364, 2008.
17. Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T et al: Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 116: 2089-2095, 2010.
18. Maekawa T, Ashihara E and Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12: 327-340, 2007. (Pubitemid 47573416)
19. Doolan CM and Keenan AK: Inhibition by fatty acids of cyclic AMP-dependent protein kinase activity in brush border membranes isolated from human placental vesicles. Br J Pharmacol 111: 509-514, 1994. (Pubitemid 24146107)
20. Soto-Guzman A, Navarro-Tito N, Castro-Sanchez L et al: Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells. Clin Exp Metastasis 27: 505-515, 2010.
21. Ragheb R, Shanab GM, Medhat AM et al: Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 389: 211-216, 2009.
22. Das Evcimen N and King GL: The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510, 2007. (Pubitemid 46962309)
23. Samuel VT, Liu ZX, Wang A et al: Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117: 739-745, 2007. (Pubitemid 46348532)